Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alendronate + calcium carbonate is a combination therapy used primarily for the treatment and prevention of osteoporosis, especially in postmenopausal women. Alendronate is a bisphosphonate that works by inhibiting osteoclast-mediated bone resorption, thereby increasing bone mineral density and reducing the risk of fractures. Calcium carbonate serves as a supplemental source of elemental calcium, which is essential for maintaining normal bone structure and function. The combination aims to both slow down bone loss (via alendronate) and ensure adequate dietary calcium intake (via calcium carbonate), supporting optimal skeletal health[1][6][7]. This combination may be provided as separate tablets or in coordinated dosing regimens but should not be taken simultaneously due to absorption interference; alendronate should be taken at least 30 minutes before any calcium supplement[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on alendronate + calcium carbonate.